{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:13:28Z","timestamp":1760238808423,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nursing Reports"],"abstract":"<jats:p>Background: High blood pressure remains one of the most important risk factors for cardiovascular disease. Although there is no consensus, all the clinical practice guidelines agree on the need to reduce blood pressure levels to minimize the risks. There are many clinical trials conducted to try to find the best pharmacotherapy to achieve this goal. The aim was to compare the main international randomized clinical trials on hypertension in people older than 50 years. Methods: Literature qualitative review of randomized clinical trials selected from PubMed and UpToDate in people older than 50 years, from 1985 until 2020. The clinical trials conducted during this period show variability in the drugs used, the inclusion criteria for blood pressure figures, and the consideration or not of other vascular risk factors (smoking, obesity, lipid disorders, diabetes, and physical inactivity). Results: Of the 8334 articles found, 19 of them fulfilled the inclusion and exclusion criteria that involved 202,638 people. The main findings of each investigation were grouped as follows: incidence of non-cardiovascular death, death of cardiovascular origin, coronary heart disease, cerebrovascular disease, renal failure, and hypertensive retinopathy. In all patients, blood pressure figures were reduced, although this did not always lead to statistically significant differences in morbidity and\/or mortality risk reduction. Twelve of them found risk reduction as an effect of reduced blood pressure. Conclusions: Randomized clinical trials conducted on hypertension in people older than 50 years of age show variability in the inclusion criteria. Variability in the antihypertensive drugs used was observed in this population. Blood pressure figures were reduced in all cases, although without statistically significant differences in morbidity and\/or mortality risk reduction.<\/jats:p>","DOI":"10.3390\/nursrep10010002","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:03:48Z","timestamp":1599555828000},"page":"2-14","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Updates in Hypertension Studies According to the Main Clinical Trials: A Review of the Past 45 Years about Pharmaceutical Intervention Effects"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-934X","authenticated-orcid":false,"given":"Jose Manuel","family":"Mart\u00ednez-Linares","sequence":"first","affiliation":[{"name":"Department of Nursing, Universidad de Ja\u00e9n, 23071 Ja\u00e9n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Danaei, G., Ding, E.L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C.J.L., and Ezzati, M. (2009). The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000058"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990\u20132015","volume":"317","author":"Forouzanfar","year":"2017","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet, 362, 1527\u20131535.","DOI":"10.1016\/S0140-6736(03)14739-3"},{"key":"ref_6","first-page":"137","article-title":"Clinical trials. A pending subject","volume":"218","year":"2018","journal-title":"Rev. Clin. Esp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","article-title":"Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki","volume":"2","author":"Rickham","year":"1964","journal-title":"Br. Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(85)91783-0","article-title":"Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial","volume":"1","author":"Amery","year":"1985","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"MRC Working Party (1992). Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ, 304, 405\u2013412.","DOI":"10.1136\/bmj.304.6824.405"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"SHEP Cooperative Research Group (1991). Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 265, 3255\u20133264.","DOI":"10.1001\/jama.265.24.3255"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","article-title":"Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension)","volume":"338","author":"Lindholm","year":"1991","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"The ALLHAT Collaborative Research Group (2000). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 283, 1967\u20131975.","DOI":"10.1001\/jama.283.15.1967"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"PROGRESS Collaborative Group (2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033\u20131041.","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Devereux","year":"2002","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288, 2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00004872-200404000-00029","article-title":"Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial","volume":"22","author":"Staessen","year":"2004","journal-title":"J. Hypertens."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of Hypertension in Patients 80 Years of Age or Older","volume":"358","author":"Beckett","year":"2008","journal-title":"N. Eng. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"The ONTARGET Investigators (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N. Eng. J. Med., 358, 1547\u20131559.","DOI":"10.1056\/NEJMoa0801317"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet, 372, 1174\u20131183.","DOI":"10.1016\/S0140-6736(08)61242-8"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"The SPRINT Research Group (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Eng. J. Med., 373, 2103\u20132116.","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","article-title":"Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease","volume":"374","author":"Lonn","year":"2016","journal-title":"N. Eng. J. Med."},{"key":"ref_26","unstructured":"U.S. National Library of Medicine (2020, March 19). Clinical Trials.gov. COlchicine for PreventioN of Vascular Inflammation in Non-CardioEmbolic Stroke (CONVINCE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02898610."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Veterans Administration Cooperative Study Group on Antihypertensive Agents (1972). Effects of treatment on mortality in hypertension III. Influence of age, diastolic blood pressure, and prior cardiovascular disease; further analysis of side effects. Circulation, 45, 991\u20131004.","DOI":"10.1161\/01.CIR.45.5.991"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.117.10177","article-title":"Effect of lowering diastolic pressure in patients with and without cardiovascular disease. Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial)","volume":"71","author":"Khan","year":"2018","journal-title":"Hypertension"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sexto Grupo de Trabajo Conjunto de la Sociedad Europea de Cardiolog\u00eda y otras Sociedades sobre Prevenci\u00f3n de Enfermedad Cardiovascular en la Pr\u00e1ctica Cl\u00ednica (2016). Gu\u00eda ESC 2016 sobre prevenci\u00f3n de la enfermedad cardiovascular en la pr\u00e1ctica cl\u00ednica. Rev. Esp. Cardiol., 69, e1\u2013e87.","DOI":"10.1016\/j.recesp.2016.08.009"},{"key":"ref_30","unstructured":"Whelton, P.K., Carey, R.M., Aronow, W.S., Casey, N.E., Collins, K.J., Himmelfarb, C.R.D., DePalma, S.M., Gidding, S., Jamerson, K.A., and Jones, D.W. (2017). 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension."},{"key":"ref_31","first-page":"859176","article-title":"Hypertension in the Elderly","volume":"2012","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1157\/13128671","article-title":"Debemos tratar la hipertensi\u00f3n arterial en el muy anciano?","volume":"208","author":"Gil","year":"2008","journal-title":"Rev. Clin. Esp."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.hjh.0000200513.48441.8e","article-title":"In a population-based prospective study no association between high blood pressure and mortality after age 85 years","volume":"24","author":"Gussekloo","year":"2006","journal-title":"J. Hypertens."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1157\/13127583","article-title":"Tratamiento del paciente de 80 o m\u00e1s a\u00f1os con hipertensi\u00f3n arterial","volume":"131","author":"Gil","year":"2008","journal-title":"Med. Clin. (Barc.)"}],"container-title":["Nursing Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-4403\/10\/1\/2\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:07:46Z","timestamp":1760177266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-4403\/10\/1\/2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["nursrep10010002"],"URL":"https:\/\/doi.org\/10.3390\/nursrep10010002","relation":{},"ISSN":["2039-4403"],"issn-type":[{"type":"electronic","value":"2039-4403"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}